Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT)

被引：0
|
作者：
Jason T. Hurwitz
Shannon Vaffis
Amy J. Grizzle
Søren Nielsen
Andrew Dodson
Suzanne Parry
机构：
[1] University of Arizona,Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy
[2] Aalborg University Hospital,NordiQC, Institute of Pathology
[3] UK National External Quality Assessment Scheme for Immunocytochemistry and In-Situ Hybridisation,undefined
来源：
Oncology and Therapy | 2022年 / 10卷
关键词：
Advanced NSCLC; Cost-effectiveness; Diagnostic; Germany; PD-L1; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：391 / 409
页数：18
相关论文
共 50 条
  • [1] Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT)
    Hurwitz, Jason T.
    Vaffis, Shannon
    Grizzle, Amy J.
    Nielsen, Soren
    Dodson, Andrew
    Parry, Suzanne
    ONCOLOGY AND THERAPY, 2022, 10 (02) : 391 - 409
  • [2] What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?
    Bravaccini, Sara
    LUNG CANCER, 2019, 132 : 152 - 153
  • [3] Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma
    Naso, Julia R.
    Wang, Gang
    Banyi, Norbert
    Derakhshan, Fatemeh
    Shokoohi, Aria
    Ho, Cheryl
    Zhou, Chen
    Ionescu, Diana N.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2021, 50
  • [4] Clinical evaluation of a laboratory-developed test using clone E1L3N for the detection of PD-L1 expression status in non-small cell lung cancer
    Xu, Hanyan
    Dong, Xidan
    Zhao, Hanxin
    Hou, Tongtong
    Chen, Chengshui
    Chen, Guorong
    Ye, Junru
    Li, Yuping
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2021, 35 (03)
  • [5] Histology versus cytology: PD-L1 testing in non-small cell lung cancer
    Takigawa, Nagio
    Ochi, Nobuaki
    Yamane, Hiromichi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S225 - S227
  • [6] Cost-effectiveness of PD-L1 testing and tumor mutational burden testing of immune checkpoint inhibitors for non-small cell lung cancer.
    Li, Wenqian
    Li, Lingyu
    Chen, Naifei
    Cui, Jiuwei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Nivolumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis including PD-L1 Testing
    Matter-Walstra, Klazien
    Schwenkglenks, Matthias
    Aebi, Stefan
    Dedes, Konstantin
    Diebold, Joachim
    Pietrini, Mario
    Klingbiel, Dirk
    Von Moos, Roger
    Gautschi, Oliver
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1430 - S1431
  • [8] PREDICTORS OF PD-L1 TESTING IN NON-SMALL CELL LUNG CANCER
    DiBonaventura, M.
    Meyers, A.
    Higginbottom, K.
    Morimoto, Y.
    Ilacqua, J.
    VALUE IN HEALTH, 2016, 19 (07) : A763 - A763
  • [9] PD-L1 Immunohistochemistry as Biomarker in Non-Small Cell Lung Cancer (NSCLC)
    Krenbek, Dagmar
    Weidinger, Barbara
    Jarius, Christa
    Holzer, Sophia
    Fabican, Hannah
    Mohn-Staudner, Andrea
    Hochmair, Maximilian
    Chott, Andreas
    Setinekl, Ulrike
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S430 - S430
  • [10] PD-L1 expression and genotype in Non-Small Cell Lung Cancer (NSCLC)
    Ansen, S.
    Schultheis, A.
    Hellmich, M.
    Leenders, F.
    Zander, T.
    Michels, S.
    Brockmann, M.
    Stoelben, E.
    Groen, H.
    Timens, W.
    Buettner, R.
    Thomas, R. K.
    Perner, S.
    Wolf, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 5 - 6
12345